Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study

Authors:

Abstract
No abstract available
Funding Information
  • North Portugal Regional Operational Programme
  • European Regional Development Fund
  • GlaxoSmithKline
  • Mundipharm
  • Novartis
  • Leti
  • Bial
  • AstraZeneca
  • GlaxoSmithKline
  • Research Foundation
  • MSD
  • Novartis
  • AstraZeneca
  • Chiesi
  • Boehringer Ingelheim
  • Sanofi
  • AstraZeneca
  • Novartis
  • UCB
  • GlaxoSmithKline
  • Teva
  • Boehringer Ingelheim
  • Chiesi
  • ASIT Biotech
  • Nuvo
  • Bayer
  • FAES
  • GlaxoSmithKline
  • MSD
  • Johnson & Johnson
  • Meda
  • OPTIMA
  • URSAPharm
  • BitopAG
  • Hulka
  • Bencard
  • Leti
  • Stallergenes
  • Lofarma
  • Roxall
  • ATMOS
  • Bionorica
  • Otonomy
  • Ferrero
  • Novartis
  • ALK-Abelló
  • Allergopharma
  • Stallergenes Greer
  • HAL Allergy Holding B.V.
  • HAL Allergie GmbH
  • Bencard Allergie GmbH
  • Allergy Therapeutics
  • Lofarma
  • Biomay
  • Nuvo
  • Circassia
  • GlaxoSmithKline
  • Biomedical Systems
  • Roche
  • Erkko Foundation
  • Gerolymatos
  • Chiesi
  • Cipla
  • Hikma
  • Menarini
  • Mundipharma
  • Mylan
  • Novartis
  • Sanofi-Aventis
  • Takeda
  • Teva
  • Uriach

This publication has 34 references indexed in Scilit: